-
FDA delays decision on Ofatumumab
It’ll be a little longer before the Food and Drug Administration decides whether it will approve Ofatumumab. That decision is now hoped for by September. Ofatumumab would be the only a monoclonal antibody therapy available as a self-injection. The rest are infusions. Sound like something you’d ask your neuro about?
-
0 Replies
Sorry, there were no replies found.
Log in to reply.